**12/6/17 | NEWS UPDATE GT Biopharma, Inc. Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease**
The recent $12 billion acquisition of Kite Pharma, Inc. by big-pharma giant, Gilead Sciences has biotech investors hungry for the next big buyout target.